Is the Compulsory Licensing Mechanism Guaranteed by TRIPS the Best Remedy to Improve Access to Biological Therapies Worldwide?
DOI:
https://doi.org/10.15290/eejtr.2019.03.01.03Słowa kluczowe:
compulsory licence, obligatory licensing, patent, biologics, biosimilars, licencesAbstrakt
A compulsory licence is an authorisation under the state administration to use intellectual property rights by third parties, subject to payment of remuneration, regardless of the patent holder's objection. In the Polish legal system, the institution of a compulsory licence is regulated by: the Paris Convention for the Protection of Industrial Property Rights (20 March 1883), the Agreement on Trade-Related Aspects of Intellectual Property Rights (15 April 1994), Regulation (EC) No 816/2006 of the European Parliament and of the Council of 17 May 2006 on the granting of compulsory licences for patents relating to the manufacture of pharmaceutical products for export to countries with public health problems and the Industrial Property Law Act (30 June 2000). The basic research thesis of my paper was based on the assumption that a compulsory licence does not meet the objective of providing access to biologics. The regulations governing this institution need to be changed, first of all towards the re-granting of a compulsory licence with the proper meaning of balancing the interests of the public (society) and private (patent holder).
Pobrania
Bibliografia
Bashaar, M., Hassali, M. A., & Saleem, F. (2017). 40th anniversary of essential medicines: a loud call for improving its access, GaBI Journal, 6(4), 174-177.
Beyer, P. (2013). Developing Socially Responsible Intellectual Property Licensing Policies: Nonexclusive Licensing Initiatives in the Pharmaceutical Sector. In J. de Werra (ed.), Research Handbook on Intellectual Property Licensing (pp. 227-256). Cheltenham, UK, Northampton, MA, USA: Edward Elgar Publishing.
Blackstone, E. A., & Fuhr, J. P. (2018). Innovation, Patents and Biologics: The Road to Biosimilar Competition: Factors Infl uencing Investment, Business Decisions and Marketing of Biosimilars. In H. J. Gutka, H. Yang, & S. Kakar (Eds.), Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (pp. 23-48). Springer International Publishing. https://doi.org/10.1007/978-3-319-99680-6_2
Bognar, C. L. F. B., Bychkovsky, B. L., & Lima de Lopes jr,, G. (2016). Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications? Journal of Global Oncology, 2(5), 292-301. https://doi.org/10.1200/JGO.2016.005363
Boldrin, M., & Levine, D. K. (2008). Against Intellectual Monopoly, Cambridge University Press.
Boulet, P. (2017). Modifier la législation européenne pour mettre en œuvre la licence d’office en France [Amend European legislation to implement the ex -officio licence in France]. Medicines Law & Policy. Retrieved from: https://medicineslawandpolicy.org/2017/11/modifier-la-legislation-europeenne-pour-mettre-en-oeuvre-la-licence-doffice-en-france/
Burich, M. (2018). The Changing US Reimbursement Landscape and Biosimilars. In H. J. Gutka, H. Yang, & S. Kakar (Eds.), Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (pp. 49-73). Springer International Publishing. https://doi.org/10.1007/978-3-319-99680-6_3
Casasempere, P.V. (2008). Resultados de los tratamientos biológicos en las enfermedades autoinmunitarias, Reumatología Clínica, 4(1), 31-34. https://doi.org/10.1016/S1699-258X(08)76137-0
Chen, B. K., Yang, Y. T., & Bennett, C. L. (2018). Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition. Drugs, 78(17), 1777–1781. https://doi.org/10.1007/s40265-018-1009-0
Cheng, W. (2019). Protection of Data in China: Seventeen Years after China’s WTO Accession, European Intellectual Property Review, 41(5), 292-297.
Cohen, A. D., Torres, T., Boehncke, W.-H., de Rie, M., Jullien, D., Naldi, L., Ryan, C., Strohal, R., Skov, L., van de Kerkhof, P., van der Walt, J. M., Wu, J. J., Zachariae, C., Puig, L., & Young, H. (2019). Biosimilars for Psoriasis – Experience from Europe, Current Dermatology Reports, 8, 26-34. https://doi.org/10.1007/s13671-019-0249-x
de Mora, F. (2019). Biosimilars: A Value Proposition. BioDrugs, 33(4), 353–356. https://doi.org/10.1007/s40259-019-00360-7
Desai, M. A. (2016). Compulsory licensing. Procedural requirements under the TRIPS agreement. Pharmaceutical Policy and Law, 18(1-4), 31-44. https://doi.org/10.3233/PPL-160430
Edwards, Ch. J., Hercogová, J., Albrand, H., Amiot, A. (2019), Switching to biosimilars: current perspectives in immune-mediated infl ammatory diseases, Expert Opinion on Biological Therapy, 1-14. https://doi.org/10.1080/14712598.2019.1610381
European Medicines Agency. (2019). Biosimilar medicines: Overview. Retrieved from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview
Favereau, E. (2017). Cancer: «La hausse des prix est devenue intenable» [Cancer: «The Price Increase Has Become Untenable»]. Libération. Retrieved from: https://www.liberation.fr/france/2017/10/24/cancer-la-hausse-des-prix-est-devenue-intenable_1605424
Frankel, S. (2019). The Continuing Excesses of Trade Agreements and the Object and Purpose of International Intellectual Property, International Review of Intellectual Property and Competition Law, 50(5), 523-526.
Geigert, J. (2019). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals. Springer Nature Switzerland AG.
Grubb, P., Thomsen, P. R., Wright, G., & Hoxie, T. (2016). Patents for Chemicals, Pharmaceuticals and Biotechnology, Oxford University Press.
Halabi, S. F. (2018). Intellectual Property and the New International Economic Order. Oligopoly, Regulation, and Wealth Redistribution in the Global Knowledge Economy. Cambridge: Cambridge University Press.
Hirschler, B. (2015). Call for Britain to over-ride patents on Roche cancer drug. Reuters. Retrieved from: http://www.reuters.com/article/roche-cancer-britain-idUSL5N1211VA20151001
Hoen, E. ‘t (2016). Private Patents and Public Health. Changing intellectual property rules for access to medicines. Amsterdam: Health Action International.
Hoen, E. ‘t (2017). Medicines Excitement in the Netherlands – New Health Minister announces firm action on “absurd” medicines pricing and gets the European Medicines Agency. Medicines Law & Policy. Retrieved from: https://medicineslawandpolicy.org/2017/11/medicines-excitementin-the-netherlands-new-health-minister-announces-firm-action-on-absurd-medicines-pricingand-gets-the-european-medicines-agency/
Hoen, E. ‘t (2018). Practical Applications of the Flexibilities of the Agreement on Trade-Related Aspects of Intellectual Property Rights. Medicines Law & Policy. Retrieved from: https://medicineslawandpolicy.org/wpcontent/uploads/2018/03/EllentHoen_dissertatie_Practical_Implications_2018.pdf
Hoen, E. ‘t, Boulet, P., & Baker, B. K. (2017). Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation. Journal of Pharmaceutical Policy and Practice, 10(1), 19. https://doi.org/10.1186/s40545-017-0107-9
Hohne, Ch. (2019). Compulsory licenses in Germany: a tool for licensing negotiations? European Pharmaceutical Review, https://www.europeanpharmaceuticalreview.com/article/84768/compulsory-licenses-in-germany-a-tool-for-licensing-negotiations/
Jain, D., Darrow, J. (2013). An Exploration of Compulsory Licensing as an Effective Policy Tool for Antiretroviral Drugs in India, Health Matrix, The Journal of Law-Medicine, 23(2), 425-457.http://scholarlycommons.law.case.edu/healthmatrix/vol23/iss2/17
Kaczor, P, Lipa, K, Jabłońska, M. J., Leis, K., Kałużny, K & Gałązka, P. (2018). Biological therapies in Crohn’s disease. Journal of Education, Health and Sport, 8(9), 643-650. http://dx.doi.org/10.5281/zenodo.1412373
Kawalec, P, Stawowczyk E., Tesar, T., Skoupa, J., Turcu-Stiolica, A., Dimitrova, M., Petrova, G. I., Rugaja, Z., Männik, A., Harsanyi, A. & Draganic, P. (2017). Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries. Frontiers in Pharmacology, 8, 288. https://doi.org/10.3389/fphar.2017.00288
Kongolo, T. (2004). Compulsory licence issues in African Arab countries. The Journal of World Intellectual Property, 7(2), 185-199. https://doi.org/10.1111/j.1747-1796.2004.tb00263.x
Kongolo, T. (2008). Unsettled International Intellectual Property Issues. Austin: Wolters Kluwer Law & Business.
Kornyo, E. A. (2017). A Guide to Bioethics. Boca Raton: CRC Press.
Krauspenhaar, D. (2015). Liability Rules in Patent Law. A Legal and Economic Analysis. BerlinHeidelberg: Springer-Verlag.
Kurki, P., & Ekman, N. (2018). EU Perspective on Biosimilars. In H. J. Gutka, H. Yang, & S. Kakar (Eds.), Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (145-169). Springer International Publishing. https://doi.org/10.1007/978-3-319-99680-6_7
Lewis, J. A. (2014). Compulsory licensing: monster or myth. UMKC Law Review, 82(4), 1055-1075
Linthorst, M. (2016). Dwing pharmaceuten tot prijsverlaging. Dat kan [Force pharmaceuticals to reduce prices. Which can]. NRC, Retrieved from: https://www.nrc.nl/nieuws/2016/10/07/dwing-pharmaceuten-tot-prijsverlaging-dat-kan-4682054-a1525464
Loveridge, S. (2017). Would Limiting Compulsory Licensing availability Under TRIPS to a List of Eligible Diseases Increase Access to Medicine in the Developing World? Bristol Law Review, (1), p. 28-53.
Lu, C., & Jacob, E. C. (2019). Biosimilars: Not Simply Generics. US Pharmacist, 44(6), 36.
Malbon, J., Lawson, Ch., & Davison, M. (2014). The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights: A Commentary. Cheltenham, UK, Northampton, MA, USA: Edward Elgar Publishing.
Manu, T. (2015). Examining the Legality of Affordability Requirements as a Substantive Condition for Granting Compulsory Licences Pursuant to the TRIPS Agreement, The Journal of World Intellectual Property, 18(6), 298-310. https://doi.org/10.1111/jwip.12038
Maraninchi, D., & Vernant, J.-P. (2016). L’urgence de maîtriser les prix des nouveaux médicaments contre le cancer [The Urgent Need to Control the Prices of New Cancer Drugs]. Le Figaro. Retrieved from: http://sante.lefigaro.fr/actualite/2016/03/14/24739-lurgence-maitriser-prix-nouveaux-medicaments-contre-cancer
Marotto, D., Ceribelli, A., & Puttini, P.S. (2019). Biosimilars: New guns for the treatment of rheumatologic patients? Beyond Rheumatology, 1(3), 15-21. https://doi.org/10.4081/br.2019.3
Matthews, D. (2017). Exclusivity for biologics. In D. Matthews & H. Zech (Eds.) Research Handbook on Intellectual Property and the Life Sciences (pp. 104-118). Cheltenham, UK, Northampton, MA, USA: Edward Elgar Publishing.
Maybarduk, P., & Rimmington, S. (2009). Compulsory Licences: a Tool to Improve Global Access to the HPV Vaccine? American Journal of Law & Medicine, 35(2-3), 323-350. https://doi.org/10.1177/009885880903500205
McKoy, J. M., & Giles, F. J. (2019). Biosimilars: Are They Really Safe? In J. M. McKoy & D. P. West (Eds.), Cancer Policy: Pharmaceutical Safety (pp. 61-73). Springer Nature Switzerland AG. https://doi.org/10.1007/978-3-319-43896-2_5
Mehta, A. (2019). Downstream Processing for Biopharmaceuticals Recovery. In D. Arora, C. Sharma, S. Jaglan, & E. Lichtfouse (Eds.), Pharmaceuticals from Microbes: The Bioengineering Perspective (pp. 163-190). Springer Nature Switzerland AG. https://doi.org/10.1007/978-3-030-01881-8_6
Mellino, M. L. (2010). The TRIPS Agreement: Helping or Hurting Least Developed Countries’ Access to Essential Pharmaceuticals? Fordham Intellectual Property, Media & Entertainment Law Journal, 20(4), 1349-1388.
Nambisan, P. (2017). An Introduction to Ethical, Safety and Intellectual Property Rights Issues in Biotechnology, Elsevier.
Nathan, J. J., Ramchandani, M., & Kaur, P. (2018). Manufacturing of Biologics. In P. S. Yamauchi (Ed.), Biologic and Systemic Agents in Dermatology (pp. 101-110). Springer International Publishing AG. https://doi.org/10.1007/978-3-319-66884-0_12
Niazi, S. K. (2016). Biosimilars and Interchangeable Biologics: Strategic Elements. Boca Raton: CRC Press.
O’Callaghan, J., Barry, S. P., Bermingham, M., Morris, J. M., & Griffin, B. T. (2019). Regulation of biosimilar medicines and current perspectives on interchangeability and policy. European Journal of Clinical Pharmacology, 75(1), 1-11. https://doi.org/10.1007/s00228-018-2542-1
Olszewska, B, Adamski, Z., & Czarnecka-Operacz, M. (2018). Quo vadis, biological treatment for psoriasis and psoriatic arthritis? Advances in Dermatology and Allergology, 35(3), 231-237. https://doi.org/10.5114/ada.2018.76086
Outterson, K. (2010). Disease-based limitations on Compulsory Licences under Articles 31 and 31bis’. In C.M. Correa (Ed.), Research Handbook on the Protection of Intellectual Property under WTO Rules: Intellectual Property in the WTO, vol. 1 (pp. 673-697). Cheltenham, UK, Northampton, MA, USA: Edward Elgar Publishing. https://doi.org/10.4337/9781849806596.00026
Pacud, Ż. (2018). Licencje przymusowe na korzystanie z wynalazków farmaceutycznych [Compulsory Licenses for the Use of Pharmaceutical Inventions]. In A. Adamczak (Ed.), 100 lat ochrony własności przemysłowej w Polsce. Księga jubileuszowa Urzędu Patentowego Rzeczypospolitej Polskiej (pp. 1508-1522). Warszawa: Wolters Kluwer.
Pawłowska, I., Pawłowski, L., Krzyżaniak, N., & Kocić, I. (2019). Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals. BioDrugs, 33(2), 183-191. https://doi.org/10.1007/s40259-019-00341-w
Pitz, J. (2019). Compulsory Licensing in the “Public Interest”. Acta Scientific Medical Sciences, 3(3), 77-80.
Ricketson, S. (2015). The Paris Convention for the Protection of Industrial Property: A Commentary. Oxford: Oxford University Press.
Rodrigues jr, E. B. (2012). The General Exception Clauses of the TRIPS Agreement. Cambridge: Cambridge University Press, https://doi.org/10.1017/CBO9781139084222
Sanchez y, C. P., & Saout, Ch. (2017). Prix et accès aux traitements médicamenteux innovants [Prices and Access to Innovative Drug Treatments]. Retrieved from: https://www.lecese.fr/sites/default/files/pdf/Avis/2017/2017_04_acces_medicaments_innovants.pdf
Schweitzer, S. O., & Lu J. Z. (2018). Pharmaceutical Economics and Policy. Oxford: Oxford University Press.
Scott Morton, F. M., Stern, A. D., & Stern, S. (2018). The Impact of the Entry of Biosimilars: Evidence from Europe. Review of Industrial Organization, 53(1), 173-210. https://10.1007/s11151-018-9630-3
Shah, V. P., & Crommelin, D. J. A. (2019). Regulatory Framework for Biosimilars. In D. J. A. Crommelin, R. D. Sindelar, & B. Meibohm, (Eds.), Pharmaceutical Biotechnology (pp. 265-274). Springer Nature Switzerland AG. https://doi.org/10.1007/978-3-030-00710-2_12
Singh, G. (2018). Biosimilars. In D. Vohora, & G. Singh (Eds.) Pharmaceutical Medicine and Translational Clinical Research (pp. 355-367). Elsevier. https://doi.org/10.1016/B978-0-12-802103-3.00023-7
Skees, S. (2007). Thai-ing up the TRIPS Agreement: Are Compulsory Licenses the Answer to Thailand’s AIDS Epidemic? Pace International Law Review, 19(2), 233-285.
Slowinski, P.R. (2018). Comment on the German Federal Supreme Court Decision “Raltegravir”. International Review of Intellectual Property and Competition Law, 49(1), 125-130. https://doi.org/10/1007/s40319-017-0662-2
Smeeding, J., Malone, D. C., Ramchandani, M., Stolshek, B., Green, L., & Schneider, P. (2019). Biosimilars: Considerations for Payers. Pharmacy and Therapeutics, 44(2), pp. 54-63.
Stankiewicz, M. (2014). Model racjonalizacji dostępu do produktu leczniczego [A Model of Rationalization of Access to a Medicinal Product], Warszawa: C. H. Beck.
Stiff, K. M., Cline, A., & Feldman, S. R. (2019). Tracking the price of existing biologics when drugs enter the market. Expert Review of Pharmacoeconomics & Outcomes Research, 19(4), 375-377. https://doi.org/10.1080/14737167.2019.1630274
Sun, H. (2003). A Wider Access to Patented Drugs Under the TRIPS Agreement. Boston University International Law Journal, 21(1), p. 101-136.
Świerczyński, M. (Ed.) (2016). Biologiczne produkty lecznicze. Aspekty prawne [Biological Medicinal Products. Legal Aspects]. Warszawa: Wolters Kluwer.
Świerczyński, M., & Więckowski, Z. (Ed.) (2019). Leczenie biologiczne a prawa pacjenta [Biological Treatment and Patient’s Rights]. Warszawa: Wolters Kluwer.
Trąbski, M. (2010). Rola patentu jako środka ochrony wynalazków farmaceutycznych – praktyka, perspektywy, problemy [The Role of the Patent as a Protection Measure of Pharmaceutical Inventions - Practice, Perspectives, Problems]. In M. Załucki (Ed.) Rozwój prawa własności intelektualnej (pp. 101-118). Warszawa: C. H. Beck.
Vakil, N., & Fanikos, J. (2019). Regulatory and Clinical Perspective on Biosimilars: A Comparison of the US and European Experiences. Current Emergency and Hospital Medicine Reports, 1-7. https://doi.org/10.1007/s40138-019-00185-2
Verduzco-Aguirre, H. C., Soto-Perez-de-Celis, E., Chavarri-Guerra, Y., & Lopes, G. (2019). Global Disparities: Can the World Afford Cancer? In E. H. Bernicker (Ed.), Cancer and Society: A Multidisciplinary Assessment and Strategies for Action (pp. 79-94). https://doi.org/10.1007/978-3-030-05855-5_6
Yamauchi, P. S. (Ed.) (2018). Biologic and Systematic Agents in Dermatology. Springer International Publishing AG. https://doi.org/10.1007/978-3-319-66884-0
Pobrania
Opublikowane
Numer
Dział
Licencja
Prawa autorskie (c) 2019 Eastern European Journal of Transnational Relations
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa 4.0 Międzynarodowe.
1. The Author declares that he or she has created the written work and holds exclusive and unlimited copyright /both moral and property rights/ and guarantees that no third parties have rights to the work.
2. In the view of the Copyright and Related Rights Act, a work must fulfill the following criterion:
a) be a manifestation of creative work,
b) have an individual character („author’s personal stamp”),
c) have a set form.
3. The Author declares that the text has not been previously published (under the same or different title, or as a part of another publication).
4. The Author allows (grants a non-exclusive license) the publishing house of University of Białystok to use the scholarly text to:
- preserve and multiply by means of any technique; save in a digital form with no limitations as to the manner and form of digital preservation;
- upload online with no limitations as to the place and time of access.
5. The Author grants consent for editorial changes made in the work.
6. The Author grants the University of Białystok rights free of charge for the duration of property copyright with no territory limits. The University has the right to grant sublicenses in the acquired rights.
7. Granting a non-exclusive license allows the Author to preserve their rights and allows other parties to make use of the work according to sublicensing agreement with provisions identical as those of Attribution 4.0 Internacional License (CC BY 4.0), available online at: https://creativecommons.org/licenses/by/4.0/. License to all its content published from 2023 and CC BY-NC-ND 4.0 to all its content published from 2017 to 2022.
8. The Agreement has been concluded for an indefinite period of time.
9. Because of costs born in preparation of the work for publishing, the Parties oblige themselves to act in good faith and refrain from declining to grant licenses.
10. To all matters not settled herein, provisions of the Civil Code and Copyright and Related Rights Act of 1994, February 4 shall apply.
11. All disputes shall be resolved by a court of local jurisdiction for the place of seat of University of Białystok.
